Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of FVD regiment (fotemustine, teniposide and dexamethasone ) for patients with primary CNS lymphoma.


Clinical Trial Description

Primary CNS lymphoma (PCNSL) is a rare B-cell variant of non-Hodgkin lymphoma that is confined to the brain, leptomeninges, spinal cord, and eyes. The optimum treatment for patients with PCNSL remains challenging and at present there is no universally accepted therapeutic approach for patients with newly diagnosed disease. The purpose of this study is to evaluate the efficacy and safety of FVD regiment(fotemustine, teniposide and dexamethasone)contrast with HD-MTX-Ara-C program for patients with primary CNS lymphoma. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01960192
Study type Interventional
Source Zhengzhou University
Contact Mingzhi zhang, Pro,Dr
Phone 13838565629
Email Mingzhi_zhang@126.com
Status Recruiting
Phase Phase 4
Start date June 2012
Completion date June 2020

See also
  Status Clinical Trial Phase
Completed NCT05274139 - Treatment of Primary CNS Lymphoma ( FTD ) Phase 2